ChemBriefSwiss drug developer Windward Bio files for US IPO
Swiss biotech firm Windward Bio filed for a US IPO on Nasdaq to fund its pipeline of long-lasting antibody treatments for asthma and inflammatory diseases. The company secured up to $365 million from
reuters · 2026-10-23 13:51